Progress in Targeting the TGFβ Pathway

Signaling by the transforming growth factor-β (TGF-β) superfamily is important in the regulation of hematopoiesis and is dysregulated in myelodysplastic syndromes (MDS), contributing to ineffective hematopoiesis and clinical cytopenias. TGF-β, activins and growth differentiation factors exert inhibitory effects on red cell formation by activating canonical SMAD2/3 pathway signaling. SMAD2/3 overactivation is seen in numerous subtypes of MDS. Furthermore, reduced levels of inhibitory SMAD7 are

References

• 1.Valcarcel D, Verma A, Platzbecker U, et al. Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. Blood. 2015;126:1669.
• 2.Suragani RN, Cawley SM, Li R, Wallner S, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014 Jun 19;123(25):3864-72.
• 3.Dussiot M, Maciel TT, Fricot A, et al. Nat Med. 2014 Apr;20(4):398-407.
• 4.

     

Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate,adaptive and targeted immunological strategies

Since the clinical introduction of anti-CD20 monoclonal antibodies into lymphoma treatment, immunologic approaches in lymphoma have made substantial progress. Advances in our understanding of tumor immunology have led to the development of strategies to overcome immunologic barriers responsible for an ineffective immune response. Specifically, therapeutic agents have been developed and tested against molecules that are responsible for T-cell exhaustion. The use of monoclonal antibodies against immune checkpoints in the adaptive immune system, such as programmed cell death-1 and cytotoxic T-lymphocyte-associated protein 4, has changed the landscape of cancer therapy including the treatment of lymphoma. This achievement has recently been accompanied by the development of novel immune checkpoint inhibitors targeting the innate immune system, including the CD47-SIRPα signaling pathway, and this approach has yielded promising results. To overcome impaired antigen presentation, antibody-based cytotoxic strategies, namely antibody-drug conjugates (polatuzumab vedotin and brentuximab vedotin) and bispecific T-cell or NK-cell engagers (blinatumomab, REGN1979, RG6206, and AFM13), have rapidly evolved with promising clinical activity. As additional tools become available for lymphoma treatment, formulation of safe, rational combination strategies to combine them with standard therapy will be of paramount importance. A successful approach to the treatment of lymphoma may require both an optimized anti-tumor immune response as well as effective depletion of malignant lymphoid cells.     

8周基础军训对入伍新兵红细胞及其相关指标的影响

目的探讨8周基础军训(basic military training,BMT)对入伍新兵血像中红细胞及其相关指标的影响,为指导科学的军事训练提供参考。方法数据来自新疆边防部队2015年度入伍的50名男性新兵,分别在BMT前后测定并记录受试新兵的红细胞计数、血红蛋白浓度及血清铁蛋白等。结果经过8周的BMT,新兵血液中血红蛋白浓度、红细胞计数及血清铁蛋白均显著下降(P0.05,P0.01)。结论 8周BMT可能导致入伍新兵发生运动性贫血,铁缺乏可能是其主要原因。     

地中海贫血孕妇产前诊断的护理效果评价

目的研究地中海贫血孕妇实施产科综合护理模式的护理配合措施及效果。方法选择78例于我院检查地中海贫血孕妇,纳入时间为2017年5月-2018年5月,采用随机数字表法将其分为综合护理组与对照组,每组均39例。其中对照组采用常规护理形式,综合护理组行产科综合护理模式,对比综合护理组与对照组护理前后心理状态评估指标及家属的护理满意度。结果护理前综合护理组与对照组患者心理状态评估指标差异无统计学意义(P>0.05),与对照组(76.92%)相比,护理后综合护理组焦虑指标、抑郁指标更低,综合护理组孕妇及家属的护理满意度(94.87%)较高(P<0.05)。结论通过综合护理模式可提升地中海贫血孕妇护理满意度,并改善其心理状态。     

贫血病人SF STfR和FEP间关系研究

目的 :研究贫血病人 SF、STf R和 FEP间的关系。方法 :测定 116例贫血病人血清中 SF、STf R和 FEP。结果 :如果以 SF<15μg/ L为界值 ,STf R和 FEP诊断 IDA的敏感度分别是 79%和 81% ,如果以 SF>2 0 0μg/ L为界值 ,STf R和 FEP诊断 IDA的特异性分别为 76 %和 5 9% ;SF<15μg/ L时 ,FEP和 STf R之间有良好的相关性 (r=0 .89,P<0 .0 0 1) ,FEP和 MCV及 STf R和 MCV之间均呈负相关 (r=- 0 .75 ,P<0 .0 0 1及 r=- 0 .72 ,P<0 .0 0 1)。结论 :对单纯 IDA病人 ,如果 SF<15 μg/ L,FEP和 STf R诊断 IDA是相当的